Depressed AIRE Gene Expression Causes Immune Cell Dysfunction &

Status Completed

Clinical Trial Summary

This study plans to learn more about Down syndrome. The investigators think there is a different level of the AIRE gene in individuals with Down syndrome. The investigators think that the AIRE gene level can provide more insight about depressed immune cell function in individuals with Down syndrome. Patients are being asked to be in this research study because the investigators want to see if their blood contains more of less of the AIRE gene.

Clinical Trial Description

Down Syndrome (DS) is the most common chromosomal abnormality among live-born infants. Through full or partial trisomy of chromosome 21, DS is associated with cognitive impairment, congenital malformations (particularly cardiovascular), and dysmorphic features. In addition, immunological abnormalities are much more prevalent in individuals with DS. For example, DS is associated with increased susceptibility to infection, as revealed in 2009 during the influenza pandemic where the likelihood of death was 300 times greater for DS patients than the general population. DS patients have increased frequencies of autoimmune disorders and leukemias, yet curiously, have a decreased risk for allergic diseases, particularly asthma. Perhaps the most telling statistic for immunologic abnormality in DS patients is that respiratory tract infections are the most important cause of mortality in DS at all ages.Our studies have identified AIRE as a master control gene that is aberrantly decreased in persons with DS, leading to autoimmunity and immunologic abnormalities. AIRE ("autoimmune regulator"), although encoded on chromosome 21, is also significantly reduced in expression in DS, where it may contribute to autoimmune and immune dysregulation. The investigators will test the hypothesis that immune dysfunction and autoimmune disease preferentially occur in DS as a consequence of deficient expression of AIRE in peripheral blood cells. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02421276
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Completed
Phase	N/A
Start date	October 19, 2015
Completion date	February 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04854122` - Blood Flow Regulation in Individuals With Down Syndrome - Training Study	N/A
Completed	`NCT04020302` - Self-Monitoring Shopping Intervention	N/A
Recruiting	`NCT01950624` - DS-Connect {TM}: The Down Syndrome Registry
Completed	`NCT04751136` - the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome	Phase 2
Completed	`NCT04767412` - Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial	N/A
Completed	`NCT04536506` - Bobath and Vojta Therapy for DS	N/A
Not yet recruiting	`NCT04037579` - Protocol for a Non-randomized Survey in Down Syndrome People Who Practice Sports. Self and Observers´ Perception.
Completed	`NCT02882698` - Performance Analysis in Down Syndrome on Mobile Phone	N/A
Completed	`NCT01791725` - A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia	Phase 2
Unknown status	`NCT01975545` - Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21	Phase 2
Completed	`NCT01808508` - Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome	N/A
Terminated	`NCT00754013` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10	Phase 3
Terminated	`NCT00754052` - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17	Phase 3
Completed	`NCT01313325` - Hippotherapy to Improve the Balance of Children With Movement Disorders	N/A
Completed	`NCT01256112` - Parent Supported Weight Reduction in Down Syndrome	N/A
Completed	`NCT01594346` - Multicenter Vitamin E Trial in Aging Persons With Down Syndrome	Phase 3
Completed	`NCT05343468` - Life Skills Improved in Children With Down Syndrome After Using Assistive Technology	N/A
Suspended	`NCT05755464` - Evaluation of Patients With Down Syndrome Compliance to Dental Therapy
Recruiting	`NCT04022460` - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed	`NCT04818437` - Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms